Chiasma's EBIT per Share for the
three
months ended in Mar. 2021 was $-0.29.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2021 was $-1.30.
During the past 3 years, the average EBIT per Share Growth Rate was -6.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 16.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Chiasma's EBIT per Share or its related term are showing as below:
CHMA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -104 Med: 6.85 Max: 25.3
Current: -6.8
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Chiasma was 25.30% per year. The lowest was -104.00% per year. And the median was 6.85% per year.
CHMA's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.6
vs CHMA: -6.80
Chiasma's EBIT for the
three
months ended in Mar. 2021 was $-18.04 Mil.
Chiasma EBIT per Share Historical Data
The historical data trend for Chiasma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiasma (NAS:CHMA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Chiasma EBIT per Share Related Terms
Thank you for viewing the detailed overview of Chiasma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Chiasma Inc is a commercial-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for rare and serious chronic disease. The US Food and Drug Administration, or the FDA, approved MYCAPSSA for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog, or SSA, approved by the FDA and the first product approved by the FDA utilizing TPE technology. The company is focused on the commercialization of MYCAPSSA for the treatment of patients with acromegaly in the United States and developing and seeking regulatory approval of MYCAPSSA in the European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHMA has been successfully added to your 